<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002080</url>
  </required_header>
  <id_info>
    <org_study_id>109A</org_study_id>
    <secondary_id>087085-999</secondary_id>
    <nct_id>NCT00002080</nct_id>
  </id_info>
  <brief_title>Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or &lt; 200: Treatment IND Study</brief_title>
  <official_title>Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or &lt; 200: Treatment IND Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay&#xD;
      Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.&#xD;
&#xD;
      Secondary: To further characterize the safety of rifabutin monotherapy in preventing or&#xD;
      delaying MAC bacteremia in HIV positive patients with CD4 counts = or &lt; 200.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Mycobacterium Avium-intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Any medication with the exception of other investigational drugs not available under a&#xD;
             treatment IND, expanded access, or parallel track program.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Confirmed HIV infection.&#xD;
&#xD;
          -  CD4 cell counts &lt;= 200 cells/mm3.&#xD;
&#xD;
          -  No evidence of disseminated MAC disease.&#xD;
&#xD;
          -  Informed consent of parent or guardian if 12 to &lt; 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Pregnant females may be eligible. There are no studies of the safety or efficacy of&#xD;
             rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the&#xD;
             potential benefit justifies the potential risk to the fetus. In addition, a&#xD;
             risk/benefit decision should consider the likelihood of a woman's developing MAC if&#xD;
             she does not receive prophylaxis. The risk of developing MAC rises substantially for&#xD;
             women with CD4 counts less than 100, although it can also develop in women with higher&#xD;
             CD4 counts. Women of reproductive potential who are not pregnant must use&#xD;
             contraception. They are encouraged to use means other than oral contraceptives.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Known hypersensitivity to rifabutin, rifampin, or other rifamycins.&#xD;
&#xD;
          -  Current infection due to MAC or other mycobacterial disease, or complaints consistent&#xD;
             with tuberculosis.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other investigational drugs with the exception of those available under a treatment&#xD;
             IND, expanded access, or parallel track program. (Licensed products prescribed for&#xD;
             unlabeled indications are not considered investigational.)&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        Prior infection due to MAC or other mycobacterial disease or complaints consistent with&#xD;
        tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PACT</name>
      <address>
        <city>Saint Davids</city>
        <state>Pennsylvania</state>
        <zip>19087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gordin F, Masur H. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS. Clin Infect Dis. 1994 Apr;18 Suppl 3:S223-6. doi: 10.1093/clinids/18.supplement_3.s223.</citation>
    <PMID>8204774</PMID>
  </reference>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Rifabutin</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Mycobacterium avium Complex</keyword>
  <keyword>Bacteremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

